LONDON (Reuters) - U.S. biotechnology group Amgen Inc has agreed to buy unlisted Decode Genetics, a pioneer in hunting down genes linked to disease, for $415 million in cash to boost its drive to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback